Hospital Infection Therapeutics Market to Reach US$ 17.8 Bn by 2026

1
Therapeutics - Anti-bacterial Drugs, Anti-fungal
Drugs, Anti-viral Drugs Infection - Hospital
Acquired Pneumonia, Urinary Tract Infections,
Gastrointestinal Disorders, Bloodstream
Infections, Surgical Site Infections, Other
Hospital Infections - Forecast 2018 - 2026
Hospital Infection Therapeutics Market
2
Table of Content
Sr. No. Content
Chapter1 Preface
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary Global Hospital Infection Therapeutics Market
Chapter 4 Market Overview
Chapter 5 Market Outlook
Chapter 6 Global Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
Chapter 7 Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Infection
Chapter 8 Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Region
Chapter 9 North America Hospital Infection Therapeutics Market Analysis and Forecast
Chapter 10 Europe Hospital Infection Therapeutics Market Analysis and Forecast
Chapter 11 Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
Chapter 12 Latin America Hospital Infection Therapeutics Market Analysis and Forecast
Chapter 13 Middle East Africa Hospital Infection Therapeutics Market Analysis and Forecast
Chapter 14 Competition Landscape

3
Hospital Infection Therapeutics Market Snapshot

• This report studies the current as well as future
  prospects of the global hospital infection
  therapeutics market.
• Increase in the geriatric population which is
  more prone to hospital-acquired infections,
  significant patient population in developing
  countries demanding proper treatment, and
  investments by public and private players for RD
  on anti-infective drugs against resistant
  bacteria are the major factors driving the global
  hospital infection therapeutics market.
• Major players operating in the global hospital
  infection therapeutics market are Merck Co.,
  Inc., Pfizer, Inc., GlaxoSmithKline plc,
  AstraZeneca, Johnson Johnson Services, Inc., F.
  Hoffmann-La Roche Ltd., Bayer AG, Allergan plc.

4
(No Transcript)
5
Reports Highlights

• global hospital infection therapeutics market was
  valued at US 14.4 Bn in 2017 and is projected to
  expand at a significant CAGR of 2.4 from 2018 to
  2026.
• Based on infection, the global hospital infection
  therapeutics market has been divided into
  hospital acquired pneumonia, surgical site
  infections, bloodstream infections,
  gastrointestinal disorders, urinary tract
  infections, and other hospital infections.
• Increase in RD to Develop Novel Antibiotics to
  Boost Market 
• Hospital acquired as well as community-associated
  infections due to highly resistant microbes
  present a major threat to public health.

Request Sample
6
(No Transcript)